"Zalcitabine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal toxic side effect is axonal degeneration resulting in peripheral neuropathy.
| Descriptor ID |
D016047
|
| MeSH Number(s) |
D03.383.742.680.245.500.950 D13.570.230.329.950 D13.570.230.500.925 D13.570.685.245.500.950
|
| Concept/Terms |
Zalcitabine- Zalcitabine
- Dideoxycytidine
- 2',3'-Dideoxycytidine
- 2',3' Dideoxycytidine
- ddC (Antiviral)
|
Below are MeSH descriptors whose meaning is more general than "Zalcitabine".
Below are MeSH descriptors whose meaning is more specific than "Zalcitabine".
This graph shows the total number of publications written about "Zalcitabine" by people in this website by year, and whether "Zalcitabine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 0 | 1 |
| 1997 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Zalcitabine" by people in Profiles.
-
Metabolism and activities of 3'-azido-2',3'-dideoxythymidine and 2',3'-didehydro-2',3'-dideoxythymidine in herpesvirus thymidine kinase transduced T-lymphocytes. Antiviral Res. 1997 Aug; 35(3):177-85.
-
Cost effectiveness of antiviral treatment with zalcitabine plus zidovudine for AIDS patients with CD4+ counts less than 300/microliters in 5 European countries. Pharmacoeconomics. 1994 Dec; 6(6):553-62.
-
Surrogate markers of disease studied as means of determining AIDS drugs' effectiveness. JAMA. 1990 Nov 14; 264(18):2362, 2365.
-
Wider access provided to AIDS drugs with actions against HIV, CMV infections. JAMA. 1990 Oct 17; 264(15):1926.